Oruka Therapeutics' CMO Joana Goncalves Sells Shares

Joana Goncalves, the Chief Medical Officer at Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 7,947 shares of the company on June 15, 2026. The shares were sold at an average price of $69.28, totaling approximately $550,595. This transaction was part of a planned sale.

Insider Buying and Selling at Oruka Therapeutics, Inc.

On June 15, 2026, Joana Goncalves made significant transactions involving Oruka Therapeutics shares. In addition to selling 7,947 shares, Goncalves also executed other transactions on the same day, including the purchase of 7,000 shares at $7.32 each. Laura Lee Sandler, the Chief Operating Officer, sold 600 shares at $69.69, while Arjun Agarwal, the Senior Vice President of Finance, sold 395 shares at the same price under a planned sale.

Other Institutional Activity in Oruka Therapeutics

FMR LLC increased its holdings in Oruka Therapeutics by 170,019 shares, ending with 7,431,403 shares valued at about $364.5 million. Venrock Adviser, LLC maintained its position with 4,148,428 shares worth approximately $203.5 million. Fairmount Funds Management LLC also held steady with 3,705,262 shares valued at around $181.7 million. BlackRock, Inc. slightly reduced its stake by 12,328 shares, holding 3,527,087 shares worth about $173 million. Paradigm Biocapital Advisors LP made a notable addition, increasing its holdings by 610,000 shares to a total of 2,320,316 shares valued at approximately $113.8 million.

Oruka Therapeutics Stock Snapshot

Shares of Oruka Therapeutics, listed on NasdaqGM under the ticker ORKA, were trading near $69.89. The company has a market capitalization of approximately $4.22 billion. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock's 52-week range is between $10.77 and $91.00, with a 50-day moving average of $63.70 and a 200-day moving average of $37.60. Oruka Therapeutics boasts a strong liquidity position with a current ratio of 23.76 and a quick ratio of 23.38, and its debt-to-equity ratio is 0.371.

Analysts Set New Price Targets

Several analysts have provided updated price targets for Oruka Therapeutics. On May 14, 2026, BTIG reiterated its buy rating with a price target of $151. HC Wainwright & Co. maintained its buy rating with a $120 target on April 29, 2026. UBS and Barclays also maintained buy ratings, with price targets of $100 and $160, respectively, on April 28, 2026. The consensus among 12 analysts is a strong buy, with a mean target price of $142.17.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. It focuses on developing innovative monoclonal antibody treatments for conditions like psoriasis and other inflammatory and immunology disorders. Key products include ORKA-001, targeting the p19 subunit of interleukin-23, and ORKA-002, targeting interleukin-17A and interleukin-17F, both in phase 2 trials. The company is led by CEO Dr. Lawrence Otto Klein and employs 68 people.

Bottom Line

Joana Goncalves' recent sale of Oruka Therapeutics shares is part of a planned transaction, reflecting typical insider activity. Oruka Therapeutics remains a strong player in the biotechnology industry, with a promising pipeline and substantial institutional interest. Analysts continue to show confidence in the stock with a strong buy consensus, despite the company's current lack of profitability.